Antisoma (LSE: ASM.L - news) shares could double if the ovarian cancer drug, R1549, is successful, and halve if it is not says the Independent. Given the probability of success, reckoned to be about 65%, that looks a gamble worth taking says the paper.

smiler
This share always has been interesting I held these years ago if they get a good deal any thing is possible with the sp.

JUST looking at the chart, Wish I got in August 14p !!

LONDON (AFX) - Cancer drug developer Antisoma PLC revealed further positive data from a phase II trial of its experimental tumour-fighting drug AS1404 in non-small cell lung cancer.

The company said in a final assessment of the data, patients who received AS1404, in addition to standard chemotherapy, were found to display a greater delay in tumour progression than previously reported.

Tumour response rates of 31 pct, compared to 22 pct for those who received chemotherapy alone, are unchanged from data revealed in June.

The data are being presented today at a meeting in Prague.

Antisoma announced last year that patients receiving AS1404 in addition to standard chemotherapy survived 5.2 months longer than those receiving chemotherapy alone, while the risk of death was reduced by 27 pct.

The company claims the result is one of the largest differences in survival ever reported from a trial combining a novel agent with first-line chemotherapy for lung cancer.

At 8.05 am shares in Antisoma were trading 1.25 pence higher at 33.5, valuing the company at 124 mln stg. The stock has more than doubled in the last three months.

Investors are waiting to hear the outcome of on-going licensing talks Antisoma is holding with potential partners for the drug, which are needed to help fund the remaining large late-stage trials.

A phase III trial is due to start next year in lung cancer. The company plans to develop the treatment as a direct competitor to Avastin, Roche AG and Genentech Inc's top-selling cancer drug, which received approval to be marketed as a treatment for lung cancer last month.

Like Avastin, AS1404 has also showed promise as a treatment for other cancers such as ovarian and prostate.

amy.brown@afxnews.com

AGM is today 17th November, 10:00 AM at Cameron McKenna, Aldersgate, should get some sort of statement or announcement.

London, UK: 24 November 2006 - Cancer drug developer Antisoma plc
(LSE: ASM; USOTC: ATSMY) today announces that its Chief Executive
Officer, Glyn Edwards, will be presenting at the Piper Jaffray 18th
Annual Health Care Conference in New York on Friday 1st December.

Mr Edwards's presentation will take place at 10.30am EST. A live
webcast of the presentation can be viewed on Antisoma's website and
available to all parties thereafter at

http://moneyam.uk-wire.com/cgi-bin/articles/20061124120200H0014.html

From another board courtesy of Mike111

I took the opportunity to make contact with ASM today, to clarify why GE had not presented at the Piper Jaffray conference on Friday and as I had suspected there was nothing sinister to this. It was a late change to his schedule which prevented him from being there and had he presented he would have gone through the same presentation delivered recently at the Rodman & Renshaw conference.

This did then allow me to address some other points which I have summarised below:

Since releasing the updated trial data on November 8th the company have witnessed sustained / increasing interest from potential licensees for AS1404
They are benefiting from the pipeline challenges faced by the major pharmas and in particular interest from those companies who have had recent issues with their own clinical trial programs
They continue to make excellent progress with negotiations for AS1404 and closure of a deal in 2006 does remain a very real possibility
Given that they have multiple options i.e. more than one interested partner, they remain committed to securing the best overall deal and will ensure that what is signed is in the best interests of all shareholders even if this takes a little longer
Comment was made that whilst ASM have always understood the value of AS1404, potential partners have now come to appreciate and accept this as well
In terms of recent trading in the stock, the company are aware that there has been increased institutional activity, as witnessed by the multitude of larger trades
At this time, they are not aware of any new notifiable interests being taken up
In particular, they have seen an increase in institutional interest from the specialist healthcare funds both in Europe and in the US. Apparently these fund managers have commented to ASM that they perceive the current share price to be low in relation to the value attaching to the companies assets i.e. primarily the value attaching to the trial data for AS1404

The bottom line is that ASM are now very close to closing the deal and at current levels this IMHO rates as a very strong buy no advice intended and DYOR.

London, UK, and Orlando, FL, 11 December 2006 - Antisoma today
announces that it is advancing AS1411 into a phase II

http://moneyam.uk-wire.com/cgi-bin/articles/20061211070000H2446.html

Very big volume today also in the Smallcap Index as of today.

Holding(s) in Company
http://moneyam.uk-wire.com/cgi-bin/articles/20061212084800H2736.html

Antisoma raises 26.3 mln stg in placing
AFX

LONDON (AFX) - Antisoma PLC has raised 26.3 mln stg in a share placing, to fund continuing ongoing research into its portfolio of experimental cancer drugs.

The company said a placing of almost 74 mln new shares with new and existing shareholders, at 35.5 pence each, was oversubscribed.

The price is a slight discount to yesterday's closing share price of 39 pence.

amy.brown@afxnews.com

ab/slm

Nice bit of money raised, and oversubscribed all good news for ASM.

From the FT today:

Back in good health after Roche move upsets market
By Salamander Davoudi

Published: December 16 2006 02:00 | Last updated: December 16 2006 02:00

Shares in Antisoma, one of the oldest UK biotechnology companies, have had their ups and downs this year but during the past three months have skyrocketed more than 150 per cent. Roche, the Swiss pharmaceutical company, last June handed back its purchase rights to Antisoma's key lung cancer drug, AS1404, and the rights to a drug for breast cancer. The markets reacted badly fearing the company would have to raise more funding to continue drug development. But the shares have since recovered on the back of positive data from a Phase II trial of AS1404. Glyn Edwards, Antisoma chief executive, has boosted confidence by indicating he is near to completing an agreement to replace Roche in order to fund the Phase III trials for AS1404. Given the high demand for cancer drugs, the future of the company could be very rosy if the drug is successful. Analysts have forecast that peak sales of AS1404 could be as high as $1bn. The company yesterday raised 26.3m in a placing with European and US institutions. The news sent the shares down 3.8 per cent to 37p - a small irritant for investors who have seen the stock come good. Salamander Davoudi

Topped up today it looks like we have hopefully hit bottom.

Some very big trades today 250k and 800k

A lot of buying today 3m, ASM is looking very strong for the next leg up.

sp regaining strength long term chart looking good break out at about 41p could come soon.

Breaking out news iminent? may be on AS1404

Tuesday January 16, 07:49 AM
Antisoma "buy," target price raised
LONDON, January 16 (newratings.com) - Analyst Mark Clark of ING Financial Markets reiterates his "buy" rating on Antisoma Plc (ticker: ASM (Milan: ASM.MI - news)

The 12-month target price has been raised from 45p to 58p.


In a research note published this morning, the analyst mentions that Antisoma (LSE: ASM.L - news) 's recent equity placement has raised 26.3 million before expenses, which has improved the company's risk profile. The placement has lowered time pressures on Antisoma for entering into a partnership for the AS1404 drug, ING Financial Markets says. The upward revision in the target price also reflects a shift in the base year, the analyst adds.

Antisoma to present at the BIO CEO conference

http://moneyam.uk-wire.com/cgi-bin/articles/20070207120000H2999.html

A bit old but explains the sp rise.

From The Business Magazine...

SANOFI-AVENTIS and AstraZeneca, the pharmaceutical giants, have opened talks with Antisoma, a British biotech firm, to license its revolutionary new cancer treatment.

Pfizer is also thought to be potentially interested in Antisomas product, which is being tested for use in the treatment of lung, prostate and ovarian cancer and could generate sales of $1.6bn (E1.23bn, 812m) a year.

The drug, currently known as AS1404, is in the third and final stages of clinical trials for lung cancer. Third stage trials for ovarian and prostate cancer will begin this year.

It works in combination with chemotherapy drugs by cutting off the blood supply to tumours, ensuring that they stop growing. This enables doctors to use lower doses of chemotherapy drugs such as carboplatin and Bristol-Myers Squibbs Taxol. The treatment has the advantage of leaving the area surrounding the tumour untouched, and will hopefully reduce the negative side effects of chemotherapy.

In the second phase of trials, patients being treated with AS1404 and chemotherapy drugs survived for over five months longer than those only using chemotherapy. Long term survival rates are not yet known.

Interest in the drug intensified after the announcement of positive data on the second stage of clinical trials. At one point the company was speaking to around 40 partners.

Glyn Edwards, Antisomas chief executive, confirmed that the company was in talks with a number of potential partners. He said: Until a deal is done, I cant name any names. AstraZeneca declined to comment. A Sanofi-Aventis spokesperson said: At this stage we cant comment.

The company is likely to receive an upfront deal of around $80m, a $200m plus sum on successful delivery of the drug to market, and between 20% and 25% of the drugs royalties.

A nice 339k buy today some things going down.